Celltrion, Inc. Drops Late-Stage Trial of Roche (RHHBY) Rituxan Drug Copy
4/18/2013 7:56:51 AM
Celltrion Inc. (068270) dropped a late-stage trial of a biosimilar version of Roche Holding AG (ROG)’s best-selling Rituxan drug, potentially benefiting competitors such as Boehringer Ingelheim GmbH and Novartis (NOVN) AG. Celltrion had planned to take its drug, CT-P10, into phase- III trials later this year, Asthika Goonewardene, a London-based analyst for Bloomberg Industries, wrote in a note today. The trial in patients with non-Hodgkin lymphoma is listed as terminated, according to the European Medicine Agency’s clinical trials register. It’s not clear what prompted the change, Goonewardene said, and if the South Korea-based company will resume the trial later.